These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8632077)

  • 1. Favorable prognostic factors in recurrent and metastatic melanoma.
    Buzzell RA; Zitelli JA
    J Am Acad Dermatol; 1996 May; 34(5 Pt 1):798-803. PubMed ID: 8632077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finally, a successful adjuvant therapy for high-risk melanoma.
    Balch CM; Buzaid AC
    J Clin Oncol; 1996 Jan; 14(1):1-3. PubMed ID: 8558183
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent cutaneous melanoma: a surgical perspective.
    Yeung RS
    Semin Oncol; 1993 Oct; 20(5):400-18. PubMed ID: 8211191
    [No Abstract]   [Full Text] [Related]  

  • 4. Thickness of malignant melanoma: global analysis of related factors.
    Kopf AW; Welkovich B; Frankel RE; Stoppelmann EJ; Bart RS; Rogers GS; Rigel DS; Friedman RJ; Levenstein MJ; Gumport SL
    J Dermatol Surg Oncol; 1987 Apr; 13(4):345-90, 401-20. PubMed ID: 3558930
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
    Dummer R; Panizzon R; Bloch PH; Burg G;
    Dermatology; 2005; 210(1):39-44. PubMed ID: 15604544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis for recurrent stage I malignant melanoma.
    Reintgen DS; Vollmer R; Tso CY; Seigler HF
    Arch Surg; 1987 Nov; 122(11):1338-42. PubMed ID: 3675198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
    Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
    Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology and prognostic factors in cutaneous malignant melanoma].
    Milo Y; Tamir G; Robinpour M; Sulkes J; Rotem A; Schachter J; Hauben DJ
    Harefuah; 1995 Jun; 128(12):745-51, 824. PubMed ID: 7557679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Consensus conference. Follow-up of patients surgically treated for stage I melanoma].
    Ann Dermatol Venereol; 1995; 122(5):250-8. PubMed ID: 8572461
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma: the management of local recurrence and in-transit metastasis.
    Couture J
    Can J Surg; 1982 Nov; 25(6):698-700. PubMed ID: 7139431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.
    Overgaard J; Gonzalez Gonzalez D; Hulshof MC; Arcangeli G; Dahl O; Mella O; Bentzen SM
    Lancet; 1995 Mar; 345(8949):540-3. PubMed ID: 7776772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of sentinel lymph nodes positive for melanoma for features predictive of non-sentinel nodal disease and patient prognosis: a 49 patient series.
    Wright EH; Stanley PR; Roy A
    J Plast Reconstr Aesthet Surg; 2010 May; 63(5):e500-2. PubMed ID: 19800304
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrence of cutaneous malignant melanoma after more than 20 years.
    Bredgaard R; Lock-Andersen J
    J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous melanoma: a model to study cancer metastasis.
    Leong SP; Gershenwald JE; Soong SJ; Schadendorf D; Tarhini AA; Agarwala S; Hauschild A; Soon CW; Daud A; Kashani-Sabet M
    J Surg Oncol; 2011 May; 103(6):538-49. PubMed ID: 21480247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma.
    Swetter SM
    J Am Acad Dermatol; 2016 Sep; 75(3):525-527. PubMed ID: 27317056
    [No Abstract]   [Full Text] [Related]  

  • 17. Loco-regional primary and recurrent melanoma: III. Update of natural history and non-systemic treatments (1980-1987).
    Lee YT
    Cancer Treat Rev; 1988 Jun; 15(2):135-62. PubMed ID: 3042128
    [No Abstract]   [Full Text] [Related]  

  • 18. Malignant melanoma.
    Califano J; Nance M
    Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
    Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
    Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
    [No Abstract]   [Full Text] [Related]  

  • 20. Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma.
    Di Filippo F; Carlini S; Garinei R; Perri P; Anzà M; Ferranti F; Saracca E; Schiratti M; Cavaliere F; Cavaliere R
    World J Surg; 1995; 19(3):359-62. PubMed ID: 7638988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.